União Europeia - português - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mieloma múltiplo - agentes antineoplásicos - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

janssen-cilag farmacÊutica ltda - teclistamabe -

União Europeia - português - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - mieloma múltiplo - agentes antineoplásicos - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.